| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-7 Days |
| Number of Subjects | 220 |
| Gender | Both Genders |
| Age Range | 1-6, 7-12, 13-17 |
| Body Types | Average |
Supplementation of the standard doses of EPs7630 to children under six years of age (10 drops thrice daily), above 12 (30 drops thrice daily) or between the two ages (20 drops thrice daily) for one week around meals noted significant reductions in overall symptoms with the onset of symptom reduction occurring within 3-4 days.
Efficacy And Tolerability Of EPs 7630 In Patients (aged 6-18 Years Old) With Acute Bronchitis
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-7 Days |
| Number of Subjects | 400 |
| Gender | Both Genders |
| Age Range | 7-12, 13-17 |
| Body Types | Average |
Supplementation of 10-30mg of EPs7630 thrice daily in youth and adolescents with acute bronchitis over a week was able to reduce symptoms as assessed by the BSS in a dose-dependent manner (although all doses were more effective than placebo).